0
0 (0%)
Silo Pharma, Inc. [UCUT]
Source:
Company Overview
Silo Pharma, Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic formulations.
| Country | United States |
| Headquarters | sarasota, florida |
| Phone Number | (718) 400-9031 |
| Industry | manufacturing |
| CEO | Eric Weisblum |
| Website | silopharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.1 |
| Operating Profit | $-4.7 |
| Net Income | $-4.4 |
| Net Cash | $0.4 |
Profit Ratios
| Gross Margin | $0.1 |
| Operating Margin | -6,526.4 |
| Profit as % of Revenues | -1.5% |
| Profit as % of Assets | -58% |
| Profit as % of Stockholder Equity | -87.3% |
Management Effectiveness
| Return on Equity | -87.3% |
| Return on Assets | -59.3% |
| Turnover Ratio | 1% |
| EBITA | $-4.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $7.4 |
| Total Liabilities | $2.4 |
| Operating Cash Flow | $-3.8 |
| Investing Cash Flow | $1 |
| Financing Cash Flow | $3.2 |
